Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BRL-301 in r/r B-cell Non-Hodgkin Lymphoma
NCT07248163Phase 1Recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BRL-301 in B-cell non-Hodgkin lymphoma, sponsored by BRL Medicine Inc. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
BRL-301
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07248163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248163.